23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6 23ME-00610, antibody targeting CD200R1: Preclinical data will be presented on targeting the CD200R1 pathway in T cells and natural killer cells using 23ME-00610 as a single agent, or in combination with other anti-tumor therapies SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ( ...

If you're an individual investor who wants to invest like a billionaire fund manager, I've got good news. Following billionaires is relatively easy because the U.S. Securities and Exchange Commission makes anyone who manages over $100 million in assets report their trading activity every quarter.In the last three months of 2023, several prominent billionaires bought shares of 23andMe (ME -8.17%) even though the stock has been plunged from its previous peak.Before plowing any of your hard-earned money into t ...

23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘ ...

SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database. These PRS reports calculate the likelihood of an individual developing one of these cancers, based on thousands of ...

What’s next for 23andMe? Most people know the biotech company as a genetic testing service. Stories of people sending their cheek swabs off in the mail only to discover that a parent who raised them wasn’t their biological one have become a kind of millennial horror genre. Of course, most 23andMe experiences aren’t that dramatic: the company says over 14 million people have used the service in hopes of learning more about their ancestry.But this month, 23andMe revealed it is facing major financial troubles, ...

23andMe Co-Founder and CEO Anne Wojcicki speaks onstage during TechCrunch Disrupt SF 2017 at Pier 48 on September 19, 2017 in San Francisco, California.Shares of the genetic testing company 23andMe sank 21% Thursday, a day after the company reported dismal third-quarter fiscal 2024 results and discussed splitting itself in two to help juice its stock price.23andMe reported revenue of $45 million for the quarter, down from the $67 million it reported in the same period last year. The company said its net los ...

Shares of 23andMe Holding Co. fell 15.8% Thursday after the DNA-testing company fiscal third-quarter sales declined 33%, weighed down by lower consumer services and research revenue. The stock’s performance puts 23andMe ME, -17.19% shares on pace for their biggest daily percentage decline since Nov. 9, 2023, they fell 21.96%, according to Dow Jones Market Data. The stock is also on pace for its fourth-worst daily percentage decline. 23andMe’s third-quarter revenue was $44.7 million, down from $66.9 milli ...

Company Participants Anne Wojcicki - Co-Founder and Chief Executive Officer Jennifer Low - Head of Therapeutics Development Conference Call Participants Operator I would like to turn the call over to Ian Cooney, Senior Director of Investor Relations at 23andMe to lead off the call. Thank you. Please go ahead. Thank you, Valerie. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the third quarter. A repla ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM___________ TO___________ Commission File Number 001-39587 __________________________________ ...

23andMe stock is down over 95% from its peak, cutting its value from $6 billion to $345 million. The genetic-testing company is facing financial and strategic challenges, and was hacked last year. The startup's backers, including Sequoia Capital, have taken big hits to their investments. NEW LOOK Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read preview Thanks for signing up! Access your favorite topics in a personalized feed while ...